Dr. Albert Bourla: I would say, Dave, do you want to say how is allocated the growth between in-line, new products and acquired products?
Dave Denton: Yes, a really good question. I think if you look at each one — each of those 3 buckets, we see growth from acquired products, we see acquired from new products and importantly, we see growth in our in-line portfolio as well. We do not anticipate nor do we see a slowdown in that perspective.
Dr. Albert Bourla: It’s approximately 1/3, 1/3, 1/3. And Angela, what about etrasimod?
Angela Hwang: I think we’re really excited about etrasimod as a new entry you see. It’s a market that has been heavily dominated by biologics and then followed by of these JAKs after the biologics. But really, in the earlier treatment positions, there really hasn’t been much innovation, and that’s where we see etrasimod fitting in. I think the safety profile of etrasimod and its efficacy allows it to be used very well as an agent prior to the use of biologics. And that’s where we see the ability to tap into a new segment and to grow.
Dr. Albert Bourla: And because I’m very excited about the product, William, would you like also to add something about it?
Dr. William Pao: Yes. I would just say we’re excited about the best-in-class profile with the study that we did, had a treat-through design. We hope and anticipate that we’ll have no black-box warning. We don’t anticipate any required for titration, the once-oral dosing, 100% of our patients were in complete remission after a year and that we’re in complete remission after one year with steroid-free. And we also have quick lymphocyte recovery after discontinuation. So, we feel all of these features potentially make etrasimod a best-in-class profile.
Dr. Albert Bourla: Sure. That’s exactly the point. Best-in-class in an area that it is poorly served right now with current solutions, so we see a lot of opportunity. Let’s go to the next question, please.
Operator: Our next question will come from Colin Bristow with UBS.
Colin Bristow: I guess, first question on COVID and to sort of piggyback on what Geoff was asking. Some of your slides and comments, you’re clearly expecting a sort of stable vaccine utilization rate, when in the last 12 months we’ve seen this number decline on a backdrop of a virus that is evolving to less clinically severe variants. And so, what underpins your confidence in these longer-term assumptions? And then also in terms of your COVID €˜23 guidance, you mentioned you’d guided to a sufficient range of variations in infection rates, et cetera. I was just wondering how much an allowance you’ve made for the potential timing or reduction in contractual orders that is the current situation with the Brussels negotiation? And then, maybe just a quick one on the pipeline DMD, this feels noticeably in the background versus other assets at the similar stage.
Just, could you update us on your level of enthusiasm and commitment to this program, especially in light of the potential competitor approval in May of this year? Thanks so much.
Dr. Albert Bourla: Thank you. DMD, Mikael?
